2026年6月最新影响因子数据已更新,欢迎查询使用。如果您对期刊系统有任何需求或者问题,欢迎反馈给我们。
![]() |
体验更多LetPub AI科研工具 >> | |
| 近期推荐: | 热 Wiley 2026暑期线上学习营 | 报名正式开启! | 热 多本ABS四星!优质经管国际期刊列表 | 新 Springer Nature生物医学与生命科学资源合集 | 附免费书单 |
| |
| 基本信息 | 登录收藏 | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字![]() | Liver Cancer LIVER CANCER (此期刊被最新的JCR期刊SCIE收录) LetPub评分 8.5
51人评分
我要评分
声誉 9.9 影响力 7.7 速度 7.0 | |||||||||||||||||||||
| 期刊ISSN | 2235-1795 | 安装APP,查看期刊最新消息
| ||||||||||||||||||||
| E-ISSN | 1664-5553 | |||||||||||||||||||||
| 2025-2026最新IF (数据来源于网友提供) | 注册或登录后,查看IF | |||||||||||||||||||||
| 实时影响因子 | 截止2026年5月06日:10.37 | |||||||||||||||||||||
| 2025-2026自引率 | 10.5%点击查看自引率趋势图 | |||||||||||||||||||||
| 五年IF (数据来源于网友提供) | 11.502数据由网友[swift_comet]收集提供 | |||||||||||||||||||||
| h-index | 25 | |||||||||||||||||||||
| CiteScore ( 2026年6月最新版) |
| |||||||||||||||||||||
| 期刊简介 |
| |||||||||||||||||||||
| 期刊官方网站 | https://www.karger.com/Journal/Home/255487 | |||||||||||||||||||||
期刊投稿格式模板 VIP专享 |
| |||||||||||||||||||||
| 期刊投稿网址 | https://www.manuscriptmanager.net/sLib/v4/login.php?paramScreen=bcN+I3CS9qwx940f/BPvJ/MzoRzVWdbdT6ew8aLp8Yk= | |||||||||||||||||||||
| 该期刊中国学者近期发文 - New | A Multicenter Phase II Study on Atezolizumab plus Bevacizumab Combination Therapy in Patients with Unresectable Hepatocellular Carcinoma and Child-Pugh Classification B Cirrhosis: CHALLENGE Trial Author: Terashima, Takeshi; Ikeda, Masafumi; Yamashita, Taro; Okusaka, Takuji; Imaoka, Hiroshi; Kawaoka, Tomokazu; Kobayashi, Satoshi; Ogasawara, Sadahisa; Hiraoka, Atsushi; Nakano, Masahito; Okano, Naohiro; Sugimoto, Rie; Moriguchi, Michihisa; Inaba, Yoshitaka; Shinoda, Satoru; Ueno, Makoto; Kudo, Masatoshi; Furuse, Junji; Nagano, Hiroaki Journal: LIVER CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1159/000551476 Immune Checkpoint Inhibitor Rechallenge in Unresectable Hepatocellular Carcinoma: A Multicenter Efficacy and Safety Study Author: Chen, Jing-Kun; Wei, Jia-Liang; Yang, Zhen-Dong; Liu, Shao-Ping; Li, Zhi-Cheng; Chen, Kang; Qin, Chuang; Su, Ze; Ye, Lin; Li, Shu-Qun; Liu, Guo-Xing; Meng, Jian-Yuan; Wu, Ying-Hui; Quan, Ting; Li, Jian; Deng, Zhu-Jian; Yang, Da-Long; Su, Jia-Yong; Chen, Guan-Lin; Dong, Cai-Yi; Gu, Bin-Yan; Li, Wen-Yang; Qin, Xiao-Shan; Long, Xiu-Qiong; Ma, Liang; Zhong, Jian-Hong Journal: LIVER CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1159/000551629 Efficacy of Nivolumab plus Ipilimumab in Advanced Hepatocellular Carcinoma with and without High-Risk Features: An International Multicenter Study Author: Kim, Jung Sun; Chen, San-Chi; Wong, Jeffrey Sum Lung; Kang, Beodeul; Lim, Ho Yeong; Kim, Ilhwan; Kim, Hyeyeong; An, Chansik; Jang, Su Jin; Kudo, Masatoshi; Tai, David; Kim, Chan; Yau, Thomas; Chon, Hong Jae Journal: LIVER CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1159/000551631 Comment on the Article Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor-Based Combination Therapy for Unresectable Hepatocellular Carcinoma Author: Liu, Mulin; Zheng, Qin; Fu, Juan Journal: LIVER CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1159/000551853 | |||||||||||||||||||||
| 期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件,不仅能满足Liver Cancer的语言要求,还能让Liver Cancer编辑和审稿人得到更好的审稿体验,让稿件最大限度地被Liver Cancer编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务(包括SCI论文英语润色,同行资深专家修改润色,SCI论文专业翻译,SCI论文格式排版,专业学术制图等)帮助作者准备稿件,已助力全球15万+作者顺利发表论文。部分发表范例可查看:服务好评 论文致谢 。
提交文稿 | |||||||||||||||||||||
| 是否OA开放访问 | No | |||||||||||||||||||||
| 通讯方式 | ALLSCHWILERSTRASSE 10, BASEL, SWITZERLAND, CH-4009 | |||||||||||||||||||||
| 出版商 | S. Karger AG | |||||||||||||||||||||
| 涉及的研究方向 | Medicine-Oncology | |||||||||||||||||||||
| 出版国家或地区 | SWITZERLAND | |||||||||||||||||||||
| 出版语言 | English | |||||||||||||||||||||
| 出版周期 | ||||||||||||||||||||||
| 出版年份 | 0 | |||||||||||||||||||||
| 年文章数 | 66点击查看年文章数趋势图 | |||||||||||||||||||||
| Gold OA文章占比 | 100.00% | |||||||||||||||||||||
| 研究类文章占比: 文章 ÷(文章 + 综述) | 86.36% | |||||||||||||||||||||
| 期刊分区表预警名单 | 2026年03月发布的新锐学术版:不在预警名单中 2025年03月发布的2025版:不在预警名单中 2024年02月发布的2024版:不在预警名单中 2023年01月发布的2023版:不在预警名单中 2021年12月发布的2021版:不在预警名单中 2020年12月发布的2020版:不在预警名单中 | |||||||||||||||||||||
| 《新锐期刊分区表》 ( 2026年3月发布) | 点击查看期刊分区表趋势图
| |||||||||||||||||||||
| 期刊分区表 ( 2025年3月升级版) |
| |||||||||||||||||||||
| 期刊分区表 ( 2023年12月旧的升级版) |
| |||||||||||||||||||||
| SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月,原SCI撤销合并入SCIE,统称SCIE) Scopus (CiteScore) Directory of Open Access Journals (DOAJ) | |||||||||||||||||||||
| PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=2235-1795%5BISSN%5D | |||||||||||||||||||||
| 平均审稿速度 | 网友分享经验: 16 Weeks | |||||||||||||||||||||
| 平均录用比例 | 网友分享经验: | |||||||||||||||||||||
| LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍,平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务(包括SCI论文英语润色,同行资深专家修改润色,SCI论文专业翻译,SCI论文格式排版,专业学术制图等)后论文在Liver Cancer顺利发表。
快看看作者怎么说吧:服务好评 论文致谢 。 提交文稿 | |||||||||||||||||||||
| 期刊常用信息链接 |
| |||||||||||||||||||||
|
|
| |
| 中国学者近期发表的论文 | |
| 1. | A Multicenter Phase II Study on Atezolizumab plus Bevacizumab Combination Therapy in Patients with Unresectable Hepatocellular Carcinoma and Child-Pugh Classification B Cirrhosis: CHALLENGE Trial Author: Terashima, Takeshi; Ikeda, Masafumi; Yamashita, Taro; Okusaka, Takuji; Imaoka, Hiroshi; Kawaoka, Tomokazu; Kobayashi, Satoshi; Ogasawara, Sadahisa; Hiraoka, Atsushi; Nakano, Masahito; Okano, Naohiro; Sugimoto, Rie; Moriguchi, Michihisa; Inaba, Yoshitaka; Shinoda, Satoru; Ueno, Makoto; Kudo, Masatoshi; Furuse, Junji; Nagano, Hiroaki Journal: LIVER CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1159/000551476 PubMed DOI |
| 2. | Immune Checkpoint Inhibitor Rechallenge in Unresectable Hepatocellular Carcinoma: A Multicenter Efficacy and Safety Study Author: Chen, Jing-Kun; Wei, Jia-Liang; Yang, Zhen-Dong; Liu, Shao-Ping; Li, Zhi-Cheng; Chen, Kang; Qin, Chuang; Su, Ze; Ye, Lin; Li, Shu-Qun; Liu, Guo-Xing; Meng, Jian-Yuan; Wu, Ying-Hui; Quan, Ting; Li, Jian; Deng, Zhu-Jian; Yang, Da-Long; Su, Jia-Yong; Chen, Guan-Lin; Dong, Cai-Yi; Gu, Bin-Yan; Li, Wen-Yang; Qin, Xiao-Shan; Long, Xiu-Qiong; Ma, Liang; Zhong, Jian-Hong Journal: LIVER CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1159/000551629 PubMed DOI |
| 3. | Efficacy of Nivolumab plus Ipilimumab in Advanced Hepatocellular Carcinoma with and without High-Risk Features: An International Multicenter Study Author: Kim, Jung Sun; Chen, San-Chi; Wong, Jeffrey Sum Lung; Kang, Beodeul; Lim, Ho Yeong; Kim, Ilhwan; Kim, Hyeyeong; An, Chansik; Jang, Su Jin; Kudo, Masatoshi; Tai, David; Kim, Chan; Yau, Thomas; Chon, Hong Jae Journal: LIVER CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1159/000551631 PubMed DOI |
| 4. | Comment on the Article Prognostic Usefulness of Clinical Complete Response after PD-1 Inhibitor-Based Combination Therapy for Unresectable Hepatocellular Carcinoma Author: Liu, Mulin; Zheng, Qin; Fu, Juan Journal: LIVER CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1159/000551853 PubMed DOI |
| 5. | Survival Benefit of Combined Systemic and Locoregional Therapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Propensity Score-Matched Analysis Author: Gao, Fan; Guo, Chengxiang; Chen, Yiwen; Shen, Yinan; Li, Xiang; Zhang, Xiaoyu; Gao, Shunliang; Bai, Xueli; Liang, Tingbo Journal: LIVER CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1159/000551935 PubMed DOI |
| 6. | Integrated Multi-Omics Profiling Identifies an Immunotherapy Vulnerable and Prognostic Associated Subtype in Cholangiocarcinoma Author: Chen, Lu; He, Yuchao; Su, Hong; Tian, Xiangdong; Liao, Haotian; Liu, Dongming; Zhao, Meng; Sun, Huichuan; Qi, Lisha; Cao, Manqing; Liu, Zhiyong; Guo, Lin; Li, Guangtao; Zhou, Chenhao; Luo, Yi; Chen, Liwei; Wu, Qiang; Cui, Yunlong; Li, Huikai; Zhu, Xiaolin; Fang, Feng; Zhang, Wei; Zhang, Shaojun; Song, Tianqiang; Guo, Hua Journal: LIVER CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1159/000550945 PubMed DOI |
| 7. | Hepatic Artery Infusion Chemotherapy for Cholangiocarcinoma in 2025 Author: Chen, Qi-Feng; Hu, Yue; Chen, Song; Jiang, Xiong-Ying; Zhao, Ming Journal: LIVER CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1159/000551430 PubMed DOI |
| 8. | Impact of Procedural Quality on Outcomes of Transarterial Chemoembolization for Hepatocellular Carcinoma: A Multicenter Study Author: Jiang, Nan; Zhang, Wen; Peng, Zhenwei; Liu, Chang; Xiao, Yu-Dong; Yang, Wei-Zhu; Ding, Rong; Yin, Li-Nan; Jiang, Jian-Qiang; Ni, Cai-Fang; Yan, Zhi-Ping; Kuang, Ming; Teng, Gao-Jun; Zhong, Bin-Yan Journal: LIVER CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1159/000550734 PubMed DOI |
| 9. | Impact of Age on Patient-Reported Outcomes with First-Line Camrelizumab plus Rivoceranib versus Sorafenib in Adults with Unresectable Hepatocellular Carcinoma: Post Hoc Analyses of the CARES-310 Open-Label, Randomized, Phase 3 Trial Author: Chan, Stephen Lam; Kaseb, Ahmed Omar; Alexander, Laura; Meng, Xianzhang; Ryan, Kristin; Shi, Wei; Vogel, Arndt Journal: LIVER CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1159/000551156 PubMed DOI |
| 10. | Age-Adjusted Charlson Comorbidity Index Guides Risk Stratification for Hepatocellular Carcinoma Patients Treated with TACE Combined with Immune Checkpoint Inhibitors and Targeted Therapy: A Multicenter Retrospective Cohort Study Author: Lin, Xiaohan; Zhang, Shiying; Ong, Meiching; Fang, Jun; Mu, Aibo; Wang, Kui; Xu, Li; Bi, Xinyu; Liu, Xiufeng; Chen, Yongjun; Sun, Huichuan; Ling, Qi Journal: LIVER CANCER. 2026; Vol. , Issue , pp. -. DOI: 10.1159/000550356 PubMed DOI |
|
|
|
投稿状态统计: 我要评分: | ||||||||||||||||
| 投稿前担心稿件结构或语言不够规范?试试稿件自查工具,一键检测 >> | ||||||||||||||||
|
||||||||||||||||
同领域作者分享投稿经验:共0条 |
||||||||||||||||
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2026 中国: LetPub上海 网站备案号:沪ICP备10217908号-1
沪公网安备号:31010402006960 (网站)31010405000484 (蝌蝌APP)
增值电信业务经营许可证:沪B2-20211595 网络文化经营许可证:沪网文[2023]2004-152号
礼翰商务信息咨询(上海)有限公司 办公地址:上海市徐汇区漕溪北路88号圣爱大厦1803室